top of page

Formulation Services

Developing Pharmaceutical Extrusion Techniques for Drug Delivery and Bioavailability

High-quality, cost-effective drug delivery techniques. CRISM Therapeutics understands how to mix active pharmaceutical ingredients with polymers and additives and the equipment to characterise solid pharmaceutical dispersions.

Solubility and Stability

The need to mix or disperse components is crucial to the pharmaceutical industry. Pharmaceutical solid dispersions are defined as the dispersion of one or more active ingredients in a matrix at solid state.
However, many poorly soluble drugs degrade at relatively low temperatures and the high shear of standard hot-melt extrusion mean that these drugs have not been evaluated by hot-melt extrusion (HME) techniques.
Many promising new pharmaceutical compounds which are perhaps hydrophobic or of low solubility have not been developed to their full potential, prompting the need for newer, extrusion techniques to clear the backlog.

While standard hot-melt extrusion can often destroy the active pharmaceutical ingredient (API) by either localised high temperature or high shear. Alternative techniques such as wet spinning and wet extrusion use harsh solvents, which can also affect the API.

Andrew Webb CEO Crism Pharmaceuticals

Andrew Webb

Chief Executive Officer

Dr Christopher McConville BSc, MSc, PhD PG Cert

Dr Christopher McConville

Chief Scientific Officer

Related team members

Interdisciplinary Experts

At CRISM Therapeutics, our team of interdisciplinary experts includes professionals in the following fields:

  • Drug Delivery

  • Materials Science

  • Pharmacology

  • Extruder Design and Operation

  • End-User Clinicians

This breadth of expertise and experience enables us to cover all aspects of formulation and development, up to clinical specifications which will lead to registration and eventual commercialisation of products.

The LSLTE Platform

Our LSLTE platform modifies the process conditions of hot-melt extrusion to enable sensitive drugs to be incorporated into approved polymers such as EVA and PLGA. This also allows for the repurposing of existing, already approved drugs to be delivered more quickly than an entirely new molecule.
This also helps with the challenge of delivering large and complex molecules (e.g., proteins) to the sites where they need to be, whether it’s deep inside the brain or simply sub-dermally. Our unique selling point is the ability to put the drug into the polymer and produce inserts or drug-loaded seeds.

Innovative Drug Delivery Techniques

bottom of page